| Endocannabinoid receptor antagonists: potential for obesity treatment. | |
| | |
MedLine Citation:
|
PMID: 15511129 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Obesity has been described as a global epidemic. Its increasing prevalence is matched by growing costs, not only to the health of the individual, but also to the medical services required to treat a range of obesity-related diseases. In most instances, obesity is a product of progressively less energetic lifestyles and the over-consumption of readily available, palatable, and highly caloric foods. Past decades have seen massive investment in the search for effective anti-obesity therapies, so far with limited success. An important part of the process of developing new pharmacologic treatments for obesity lies in improving our understanding of the psychologic and physiologic processes that govern appetite and bodyweight regulation. Recent discoveries concerning the endogenous cannabinoids are beginning to give greater insight into these processes. Current research indicates that endocannabinoids may be key to the appetitive and consummatory aspects of eating motivation, possibly mediating the craving for and enjoyment of the most desired, most fattening foods. Additionally, endocannabinoids appear to modulate central and peripheral processes associated with fat and glucose metabolism. Selective cannabinoid receptor antagonists have been shown to suppress the motivation to eat, and preferentially reduce the consumption of palatable, energy-dense foods. Additionally, these agents act to reduce adiposity through metabolic mechanisms that are independent of changes in food intake. Given the current state of evidence, we conclude that the endocannabinoids represent an exciting target for new anti-obesity therapies. |
| | |
Authors:
|
Tim C Kirkham; Claire M Williams |
Related Documents
:
|
19328819 - Relation of obesity to consummatory and anticipatory food reward. 18574849 - The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the... 10333369 - Leptin in human reproduction. 15050599 - Exposure to appetitive food stimuli markedly activates the human brain. 21168249 - Food security and humanitarian assistance among displaced iraqi populations in jordan a... 10340819 - Sensory and hedonic associations with macronutrient and energy intakes of lean and obes... 17852499 - Nutritional quality of organic, conventional, and seasonally grown broccoli using vitam... 11878039 - Dietary recommendations for neutropenic patients. 18551109 - Polymorphisms of the fto gene are associated with variation in energy intake, but not e... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Treatments in endocrinology Volume: 3 ISSN: 1175-6349 ISO Abbreviation: Treat Endocrinol Publication Date: 2004 |
Date Detail:
|
Created Date: 2004-10-29 Completed Date: 2005-02-08 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 101132977 Medline TA: Treat Endocrinol Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 345-60 Citation Subset: IM |
Affiliation:
|
School of Psychology, The University of Liverpool, Liverpool L69 7ZA, UK. t.c.kirkham@liv.ac.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Endocannabinoids
/
metabolism* Humans Obesity / drug therapy* Receptors, Cannabinoid / antagonists & inhibitors* |
| Chemical | |
Reg. No./Substance:
|
0/Endocannabinoids; 0/Receptors, Cannabinoid |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Potential adjunctive therapies in adolescents with type 1 diabetes mellitus.
Next Document: Combining bisphosphonates with hormone therapy for postmenopausal osteoporosis.